Loading...
Loading...
On August 1, 2012, Forest received a warning letter from the FDA, regarding a
violation of Daliresp promotional practices by its sales reps. This warning
letter follows another warning letter from the FDA in April 2011 regarding
unethical sales practices by a Forest sales rep concerning Savella.
Importantly, both of these letters were issued AFTER Forest's settlement with
the US Department of Justice in September 2010 regarding similar unethical
sales practices pursuant to which Forest pled guilty to a felony charge, paid
over $300 million in fines and signed a 5-year Corporate Integrity Agreement
to resolve these matters.
It is obviously worrisome that these practices would be ongoing at Forest
given its chequered history in similar matters. In fact, Forest has received
2 of the last 43, or about 5%, of all warning letters of this type issued by
the FDA in the last 18 months despite thousands of products being promoted by
hundreds of companies. And more importantly, Forest is one of the only
companies lax enough to receive multiple warning letters while subject to a
Corporate Integrity Agreement. Moreover, it is alarming that the FDA
specifically states in the warning letter that it is concerned given the
pre-existing requirements under the Corporate Integrity Agreement. It should
be noted that Forest previously disclosed that "failure to comply with the
terms of the Corporate Integrity Agreement could result in substantial
penalties and potential exclusion from government health care programs" and
this is a potential breach of Forest's obligations under that agreement.
And why wouldn't Forest disclose this to shareholders in the 10-Q it filed on
Friday, August 10, 2012. I am sure they will say that they were advised that
they could get away without disclosure. But that is neither the right answer
for shareholders nor the right message to the management. In fact, I believe
that Forest has been very aggressive in its lack of disclosure with the SEC –
many of their major license agreements are not publicly filed with the SEC
even though all material agreements are required to be filed with the SEC and
they have been opaque on their succession plans, to name just a few
deficiencies.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in